Since the early 2000s, vaccines targeting ten major diseases have prevented 37 million child deaths across 98 low- and middle-income countries (LMICs), according to rigorous modeling by 16 independent research groups. Projections indicate this figure could double by 2030.
Over the past two decades, vaccination programs focused on children in LMICs have expanded dramatically. A landmark study quantified their impact by modeling ten key pathogens in 98 countries.
The pathogens include: hepatitis B virus, Haemophilus influenzae type b, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, Streptococcus pneumoniae, rotavirus, rubella, and yellow fever.
The results are striking: Since 2000, these vaccines have averted 37 million deaths in the studied countries. Notably, children born in 2019 in these 98 LMICs who remain unvaccinated face a 45% higher risk of dying before age five.
The benefits extend into adulthood, with vaccinated children born in 2019 experiencing 72% lower lifetime mortality from these diseases.
Across the lifetimes of those born from 2000 to 2030, vaccinations are projected to prevent 120 million deaths, including 96 million from measles and hepatitis B vaccines alone.
“Our study demonstrates the tremendous health benefits achievable through immunization programs in low- and middle-income countries,” says epidemiologist Neil Ferguson of Imperial College London. “By projecting to 2030 across these 98 countries, we provide clear insights into where to direct investments for maximum impact.”
While the model relies on estimates due to limited empirical data on disease burden in many countries, it represents the most comprehensive analysis to date, underscoring the proven value of global immunization efforts.
